Armistice Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Armistice Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123M	Buy	2,646,201 +750,854	+40%	+$36.1M	1.51%	5
2026 Q1	$98M	Sell	1,895,347 -868,653	-31%	-$44.2M	1.74%	8
2025 Q4	$137M	Sell	2,764,000 -72,000	-3%	-$3.5M	1.63%	7
2025 Q3	$136M	Sell	2,836,000 -1,976,000	-41%	-$79.6M	2.01%	5
2025 Q2	$152M	Sell	4,812,000 -384,000	-7%	-$12.3M	2.62%	4
2025 Q1	$170M	Buy	5,196,000 +360,000	+7%	+$12.8M	2.55%	4
2024 Q4	$175M	Sell	4,836,000 -260,000	-5%	-$9.16M	2.39%	4
2024 Q3	$159M	Sell	5,096,000 -176,000	-3%	-$5.49M	2.54%	4
2024 Q2	$141M	Buy	5,272,000 +1,700,000	+48%	+$49.3M	1.77%	4
2024 Q1	$122M	Sell	3,572,000 -1,078,000	-23%	-$32.1M	1.62%	6
2023 Q4	$135M	Sell	4,650,000 -442,000	-9%	-$11.7M	1.84%	5
2023 Q3	$140M	Buy	5,092,000 +56,000	+1%	+$1.7M	2.15%	3
2023 Q2	$151M	Buy	5,036,000 +686,000	+16%	+$24M	2.19%	4
2023 Q1	$158M	Sell	4,350,000 -6,000	-0.1%	-$231K	2.27%	5
2022 Q4	$155M	Sell	4,356,000 -237,004	-5%	-$8.24M	2.71%	4
2022 Q3	$155M	Sell	4,593,004 -118,996	-3%	-$3.87M	2.7%	4
2022 Q2	$136M	Buy	4,712,000 +1,612,000	+52%	+$46.2M	2.38%	5
2022 Q1	$100M	Sell	3,100,000 -1,036,000	-25%	-$31.8M	1.94%	10
2021 Q4	$121M	Buy	4,136,000 +236,000	+6%	+$7.16M	1.97%	7
2021 Q3	$104M	Buy	3,900,000 +576,000	+17%	+$15.5M	1.76%	10
2021 Q2	$102M	Sell	3,324,000 -88,000	-3%	-$2.7M	1.83%	8
2021 Q1	$89.3M	Buy	3,412,000 +292,000	+9%	+$8.17M	2.05%	6
2020 Q4	$78.5M	Sell	3,120,000 -80,000	-3%	-$1.72M	2.67%	4
2020 Q3	$66.7M	Buy	3,200,000 +992,000	+45%	+$22.5M	2.42%	4
2020 Q2	$52.4M	Sell	2,208,000 -792,000	-26%	-$17.5M	2.3%	11
2020 Q1	$54M	Buy	3,000,000 +1,288,000	+75%	+$27.1M	3.34%	4
2019 Q4	$40.6M	Buy	+1,712,000	New	+$41.6M	2.34%	7

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital's SUPN Position: Q2 2026 in Review

Armistice Capital increased its Supernus Pharmaceuticals (SUPN) stake by 40% in Q2 2026, buying an estimated $36.1M and bringing the position to 2,646,201 shares worth $123M. The position accounts for 1.51% of the portfolio, ranked #5.

Armistice Capital first reported a position in SUPN in Q4 2019 and has held it in 27 quarters since. The position peaked at $175M in Q4 2024. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Armistice Capital held 2,646,201 shares of Supernus Pharmaceuticals worth $123M as of Q2 2026.
Armistice Capital bought 750,854 Supernus Pharmaceuticals shares in Q2 2026, an estimated $36.1M.
Supernus Pharmaceuticals made up 1.51% of Armistice Capital's portfolio in Q2 2026, its #5 holding.
Armistice Capital first reported a position in Supernus Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
Armistice Capital's Supernus Pharmaceuticals position peaked at $175M in Q4 2024.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.